(E)-1-(3-Bromo­phen­yl)-3-(4-ethoxy­phen­yl)prop-2-en-1-one

The title compound, C17H15BrO2, adopts an E configuration. The dihedral angle between the two benzene rings is 10.09 (11)°. The enone plane makes dihedral angles of 12.05 (11) and 9.87 (11)°, respectively, with the bromo­phenyl and ethoxy­phenyl rings. The eth­oxy group is nearly coplanar with the attached benzene ring. In the crystal structure, the mol­ecules are linked by C—H⋯O hydrogen bonds, forming a zigzag ribbon-like structure along the b-axis direction

Conserved Expression Signatures between Medaka and Human Pigment Cell Tumors

Aberrations in gene expression are a hallmark of cancer cells. Differential tumor-specific transcript levels of single genes or whole sets of genes may be critical for the neoplastic phenotype and important for therapeutic considerations or useful as biomarkers. As an approach to filter out such relevant expression differences from the plethora of changes noted in global expression profiling studies, we searched for changes of gene expression levels that are conserved. Transcriptomes from massive parallel sequencing of different types of melanoma from medaka were generated and compared to microarray datasets from zebrafish and human melanoma. This revealed molecular conservation at various levels between fish models and human tumors providing a useful strategy for identifying expression signatures strongly associated with disease phenotypes and uncovering new melanoma molecules

Characterisation of the dip-bump structure observed in proton-proton elastic scattering at root s=8 TeV

The TOTEM collaboration at the CERN LHC has measured the differential cross-section of elastic proton-proton scattering at root s = 8 TeV in the squared four-momentum transfer range 0.2 GeV2 < vertical bar t vertical bar < 1.9 GeV2. This interval includes the structure with a diffractive minimum ("dip") and a secondary maximum ("bump") that has also been observed at all other LHC energies, where measurements were made. A detailed characterisation of this structure for root s = 8 TeV yields the positions, vertical bar t vertical bar(dip) = (0.521 +/- 0.007) GeV2 and vertical bar t vertical bar(bump) = (0.695 +/- 0.026) GeV2, as well as the cross-section values, d sigma/dt vertical bar(dip) = (15.1 +/- 2.5) mu b/GeV2 and d sigma/dt vertical bar(bump) = (29.7 +/- 1.8) mu b/Ge-2, for the dip and the bump, respectively

MyPal-Child study protocol:An observational prospective clinical feasibility study of the MyPal ePRO-based early palliative care digital system in paediatric oncology patients

Introduction Electronic patient-reported outcomes (ePROs) have tremendous potential to optimise palliative and supportive care for children with cancer, their families and healthcare providers. Particularly, these children and their families are subjected to multiple strains caused by the disease and its treatment. The MyPal digital health platform is designed to address these complex demands by offering pursuant ePRO-based functionalities via two mobile applications, one developed for children and the other for their parents. Methods and analysis In this observational prospective feasibility study, 100 paediatric oncology patients aged between 6 and 17 years and at least one of their parents/legal guardians will be recruited at three clinical sites in two European countries (Germany and Czech Republic). They will use the mobile applications which are part of the novel digital health platform. During a 6-month study period, participants will complete various ePROs via the applications addressing quality of life, satisfaction with care and impact of the disease on the family at monthly intervals. Additionally, priority-based symptom reporting is integrated into a serious game for children. Outcomes that will be assessed concern the feasibility and the evaluation of the newly designed digital health platform to contribute to the evidence base of clinical ePRO use in paediatric oncology and palliative care process. Ethics and dissemination The MyPal-Child study obtained ethical approval from the Ethics Committee responsible for the University of Saarland, that is, the Ärztekammer des Saarlandes, the Ethics Committee of the Medical School Hannover and the Ethics Committee of the University of Brno. Study results will be disseminated through scientific publications, presentations at international conferences, congresses and a final report to the European Commission. General publicly accessible information can be found on the project website (www.mypal-project.eu) and social media. © 2021 Author(s)

Measurement of the proton-antiproton total cross section at the SppS collider by a luminosity dependent method

The proton-antiproton total cross section was measured at the center-of-mass energy of s = 541GeV at the SppS at CERN using a luminosity dependent method. The result \u3c3tot=63.0\ub12.1 mb is in agreement with the luminosity independent measurement performed earlier by the UA4 Collaboration